{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T08:44:05Z","timestamp":1790671445159,"version":"4.1.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Ernst-und-Berta-Grimmke Foundation, grant reference number: 18\/24"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To report three-year outcomes undergoing PAUL\u00ae Glaucoma Implant (PGI) surgery in a single-centre cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective cohort study including patients undergoing PGI surgery at the University Eye Hospital Bonn, Germany, from April to September 2021. Patients were enrolled in a database at the time of surgery, with follow-up data collected at each visit. The primary outcome was the success rate based on predefined IOP criteria (A\u2009\u2264\u200921, B\u2009\u2264\u200918, C\u2009\u2264\u200915, and D\u2009\u2264\u200912\u2009mmHg). Secondary outcomes included IOP, BCVA, IOP-lowering medications, complications, and intraluminal Prolene stent removal.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Sixty eyes of 56 patients were included. Qualified and complete success rates (95% CI) were 88% (80\u201397) and 43% (30\u201356) for Criterion A, 67% (53\u201378) and 37% (23\u201350) for Criterion B, 43% (30\u201357) and 27% (15\u201339%) for Criterion C and 30% (18\u201342) and 22% (12\u201333) for Criterion D. Mean IOP decreased from 26.73\u2009mmHg (7\u201348) to 10.83\u2009mmHg (4\u201320) (reduction of 54%) over 36 months with a reduction in IOP-lowering agents from 3.38 to 0.57. Three eyes developed hypotony requiring intervention, one required DMEK for corneal decompensation, and seven required conjunctival revision for tube exposure. The Prolene stent was removed in 29 eyes (49.2%) after a mean of 4.44 months, reducing IOP from 23.58 to 12.04\u2009mmHg.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>PGI surgery effectively reduces IOP and medication burden in refractory glaucoma, with sustained efficacy over three years. The intraluminal Prolene stent enables further non-invasive IOP reduction postoperatively.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41433-025-04131-3","type":"journal-article","created":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T08:46:00Z","timestamp":1765874760000},"page":"334-340","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical outcomes of the PAUL\u00ae Glaucoma implant for refractory glaucoma: three-year results"],"prefix":"10.1038","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9714-2851","authenticated-orcid":false,"given":"Constance","family":"Liegl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonie","family":"Bourauel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Aretz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Walz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Hundertmark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Petrak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8019-9272","authenticated-orcid":false,"given":"Frank G.","family":"Holz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Mercieca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,16]]},"reference":[{"key":"4131_CR1","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1159\/000458485","volume":"59","author":"AA Aref","year":"2017","unstructured":"Aref AA, Gedde SJ, Budenz DL. Glaucoma drainage implant surgery. Dev Ophthalmol. 2017;59:43\u201352.","journal-title":"Dev Ophthalmol"},{"key":"4131_CR2","doi-asserted-by":"publisher","first-page":"3202","DOI":"10.1038\/s41433-021-01595-x","volume":"35","author":"ICF Pereira","year":"2021","unstructured":"Pereira ICF, van de Wijdeven R, Wyss HM, Beckers HJM, den Toonder JMJ. Conventional glaucoma implants and the new MIGS devices: a comprehensive review of current options and future directions. Eye (Lond). 2021;35:3202\u201321.","journal-title":"Eye (Lond)"},{"key":"4131_CR3","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/cts.12660","volume":"13","author":"RMH Lee","year":"2020","unstructured":"Lee RMH, Bouremel Y, Eames I, Brocchini S, Khaw PT. Translating minimally invasive glaucoma surgery devices. Clin Transl Sci. 2020;13:14\u201325.","journal-title":"Clin Transl Sci"},{"key":"4131_CR4","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1016\/j.ophtha.2016.06.035","volume":"123","author":"PG Christakis","year":"2016","unstructured":"Christakis PG, Kalenak JW, Tsai JC, Zurakowski D, Kammer JA, Harasymowycz PJ, et al. The Ahmed versus Baerveldt study: five-year treatment outcomes. Ophthalmology. 2016;123:2093\u2013102.","journal-title":"Ophthalmology"},{"key":"4131_CR5","doi-asserted-by":"publisher","first-page":"xii","DOI":"10.1016\/j.ajo.2015.12.031","volume":"163","author":"EJ Rockwood","year":"2016","unstructured":"Rockwood EJ. The Ahmed Baerveldt Comparison (ABC) study: long-term results, successes, failures, and complications. Am J Ophthalmol. 2016;163:xii\u2013xiv.","journal-title":"Am J Ophthalmol"},{"key":"4131_CR6","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1097\/IJG.0000000000000135","volume":"25","author":"E Sharkawi","year":"2016","unstructured":"Sharkawi E, Artes PH, Oleszczuk JD, Bela C, Achache F, Barton K, et al. Systematic occlusion of shunts: control of early postoperative iop and hypotony-related complications following glaucoma shunt surgery. J Glaucoma. 2016;25:54\u201361.","journal-title":"J Glaucoma"},{"key":"4131_CR7","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1097\/IJG.0000000000002369","volume":"33","author":"MCJ Tan","year":"2024","unstructured":"Tan MCJ, Ong CW, Aquino MC, Lun KW, Sng CCA, Lim DKA, et al. Three-year outcomes of the Paul Glaucoma Implant for treatment of glaucoma. J Glaucoma. 2024;33:478\u201385.","journal-title":"J Glaucoma"},{"key":"4131_CR8","doi-asserted-by":"crossref","unstructured":"Richardson J, Tacea F, Yu J, Yau K, Fenerty C, Au L. The PAUL Glaucoma Implant in the management of uveitic glaucoma-3-year follow-up. Eye (Lond). 2025;39:931\u20137.","DOI":"10.1038\/s41433-024-03527-x"},{"key":"4131_CR9","doi-asserted-by":"crossref","unstructured":"Vallabh NA, Mason F, Yu JTS, Yau K, Fenerty CH, Mercieca K, et al. Surgical technique, perioperative management and early outcome data of the PAUL\u00ae glaucoma drainage device. Eye (Lond). 2022;36:1905\u201310.","DOI":"10.1038\/s41433-021-01737-1"},{"key":"4131_CR10","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.ogla.2020.05.001","volume":"3","author":"V Koh","year":"2020","unstructured":"Koh V, Chew P, Triolo G, Lim KS, Barton K. Treatment Outcomes Using the PAUL Glaucoma Implant to Control Intraocular Pressure in Eyes with Refractory Glaucoma. Ophthalmol Glaucoma. 2020;3:350\u20139.","journal-title":"Ophthalmol Glaucoma"},{"key":"4131_CR11","doi-asserted-by":"crossref","unstructured":"Jos\u00e9 P, Bar\u00e3o RC, Teixeira FJ, Marques RE, Peschiera R, Barata A, et al. One-Year Efficacy and Safety of the PAUL Glaucoma Implant Using a Standardized Surgical Protocol. J Glaucoma. 2021.","DOI":"10.1097\/IJG.0000000000001969"},{"key":"4131_CR12","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1111\/ceo.14235","volume":"51","author":"C Weber","year":"2023","unstructured":"Weber C, Hundertmark S, Liegl R, Jauch AS, Stasik I, Holz FG, et al. Clinical outcomes of the PAUL\u00ae glaucoma implant: one-year results. Clin Exp Ophthalmol. 2023;51:566\u201376.","journal-title":"Clin Exp Ophthalmol"},{"key":"4131_CR13","unstructured":"R Core Team. R: A Language and Environment for Statistical Computing. 2021."},{"key":"4131_CR14","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1097\/IJG.0000000000001998","volume":"31","author":"MCJ Tan","year":"2022","unstructured":"Tan MCJ, Choy HYC, Koh Teck Chang V, Aquino MC, Sng CCA, Lim DKA, et al. Two-year outcomes of the Paul Glaucoma Implant for treatment of glaucoma. J Glaucoma. 2022;31:449\u201355.","journal-title":"J Glaucoma"},{"key":"4131_CR15","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1097\/00061198-199602000-00006","volume":"5","author":"JA Prata Jr","year":"1996","unstructured":"Prata JA Jr, Minckler DS, Mermoud A, Baerveldt G. Effects of intraoperative mitomycin-C on the function of Baerveldt glaucoma drainage implants in rabbits. J Glaucoma. 1996;5:29\u201338.","journal-title":"J Glaucoma"},{"key":"4131_CR16","doi-asserted-by":"publisher","first-page":"3273","DOI":"10.1007\/s00417-024-06476-z","volume":"262","author":"R Figueiredo","year":"2024","unstructured":"Figueiredo R, Barbosa-Breda J. The efficacy of adjunctive mitomycin C and\/or anti-VEGF agents on glaucoma tube shunt drainage device surgeries: a systematic review. Graefes Arch Clin Exp Ophthalmol. 2024;262:3273\u201386.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"4131_CR17","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1097\/IJG.0000000000002457","volume":"33","author":"C Weber","year":"2024","unstructured":"Weber C, Hundertmark S, Stasik I, Holz FG, Mercieca K. Two-year clinical outcomes of the PAUL glaucoma implant in white patients with refractory glaucoma. J Glaucoma. 2024;33:808\u201314.","journal-title":"J Glaucoma"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-04131-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-04131-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-04131-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T10:07:20Z","timestamp":1770372440000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-04131-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,16]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["4131"],"URL":"https:\/\/doi.org\/10.1038\/s41433-025-04131-3","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,16]]},"assertion":[{"value":"22 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"CL, LB, BA, WW, SH and MP certify that they have no affiliations with or involvement in any organisation or entity with any financial interest (such as honoraria; educational grants; participation in speakers\u2019 bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript. KM has received honoraria or research grants from the following: Allergan\/Abbvie (C,H,R) and Glaukos (C,H,R), but none of this is related to the current study. FGH has received honoraria or research grants from the following: Acucela (C,F), Allergan (F), Apellis (C, F), Bayer (C, F), Boehringer-Ingelheim (C), Bioeq\/ Formycon (F,C), CenterVue (F), Ellex (F), Roche\/Genentech (C,F), Geuder (C,F), Graybug (C), Gyroscope (C), Heidelberg Engineering (C,F), IvericBio (C, F), Kanghong (C,F), LinBioscience (C), NightStarX (F), Novartis (C,F), Optos (F), Oxurion (C), Pixium Vision (C,F), Oxurion (C), Stealth BioTherapeutics (C), Zeiss (F,C), but none of this is related to the current study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study protocol was reviewed and approved by ethics review board at the University of Bonn, \u201cEthikkommission der Universit\u00e4t Bonn\u201d, approval number 458\/21.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"No written informed consent was obtained from participants to participate in the study. Due to the retrospective character of this study and since used data does not allow to identify patients, a waiver of informed consent was obtained by the local ethics committee. The ethics review board at the University of Bonn, \u201cEthikkommission der Universit\u00e4t Bonn\u201d gave a waiver under the reference number 258\/21. The research was conducted ethically in accordance with the World Medical Association Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}